direct oral anticoagulants
Summary
Direct oral anticoagulants (DOACs) are oral anticoagulants that directly inhibit specific clotting factors—either factor Xa (apixaban, rivaroxaban, edoxaban) or thrombin/factor IIa (dabigatran)—without requiring antithrombin as a cofactor. They are used for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of venous thromboembolism (DVT/PE), and post-orthopedic surgery prophylaxis. Compared to warfarin, they have rapid onset, fewer drug/food interactions, and do not require routine INR monitoring.
Detail
DOACs work by directly and selectively inhibiting a single coagulation factor in the clotting cascade, unlike warfarin which inhibits vitamin K epoxide reductase affecting multiple factors (II, VII, IX, X). Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) block the conversion of prothrombin to thrombin by inhibiting free and clot-bound factor Xa. Dabigatran, a direct thrombin inhibitor, binds directly to the active site of thrombin (factor IIa), preventing fibrinogen cleavage to fibrin and inhibiting platelet activation.
Clinical uses include: prevention of stroke/systemic embolism in nonvalvular atrial fibrillation, treatment and secondary prevention of VTE (DVT/PE), and thromboprophylaxis after hip/knee replacement surgery. They are NOT recommended in mechanical heart valves or valvular (rheumatic) atrial fibrillation, as they were less effective than warfarin in these settings (per RE-ALIGN trial).
Advantages over warfarin: predictable pharmacokinetics allowing fixed dosing without routine monitoring, fewer dietary/drug interactions, rapid onset/offset (useful for bridging), and similar or lower rates of major bleeding (especially intracranial hemorrhage).
Key pharmacologic considerations: Renal clearance varies (dabigatran ~80% renally cleared, requiring dose adjustment or avoidance in renal impairment; apixaban has the least renal dependence). Reversal agents exist: idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors. Activated charcoal can be used if ingestion is recent.
Monitoring: Routine coagulation studies (PT/INR, aPTT) are not reliable for quantifying DOAC effect, though dabigatran can prolong aPTT/thrombin time, and Xa inhibitors can mildly affect PT. Specific anti-Xa assays or dilute thrombin time (Hemoclot) can quantify drug levels when needed (e.g., before urgent surgery or in bleeding/overdose).
Adverse effects: Bleeding (though less intracranial bleeding than warfarin), GI upset, and dabigatran-specific dyspepsia. Use caution in renal/hepatic impairment and avoid in pregnancy.
Sources
- Katzung's Basic and Clinical Pharmacology
- First Aid for the USMLE Step 1
- UpToDate: Direct oral anticoagulants (DOACs)
- Goldman-Cecil Medicine
Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.